Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2009 by Shahid Beheshti University of Medical Sciences.
Recruitment status was  Recruiting
Information provided by:
Shahid Beheshti University of Medical Sciences
ClinicalTrials.gov Identifier:
First received: May 4, 2009
Last updated: NA
Last verified: May 2009
History: No changes posted
This randomized, controlled trial (RCT) compares the efficacy and safety of Ahmed Glaucoma Valve (AGV) implantation alone, with 3 minutes MMC application or with a single layer coverage of amniotic membrane. Outcomes include intraocular eye pressure (IOP), postoperative glaucoma medication and complications. AGV implantation site will be superior or inferior based on indication and these groups will be randomized separately.

Condition Intervention Phase
Refractory Glaucoma
Device: Ahmed Glaucoma Valve (AGV)
Drug: Mitomycin C (MMC)
Procedure: amniotic membrane coverage
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Ahmed Glaucoma Valve Alone,With Amniotic Membrane or With MMC for Treatment of Refractory Glaucoma

Resource links provided by NLM:

Further study details as provided by Shahid Beheshti University of Medical Sciences:

Arms Assigned Interventions
Experimental: Ahmed Glaucoma Valve (AGV) alone Device: Ahmed Glaucoma Valve (AGV)
AGV implantation
Experimental: AGV plus MMC Device: Ahmed Glaucoma Valve (AGV)
AGV implantation
Drug: Mitomycin C (MMC)
3 minute MMC application
Experimental: AGV plus amniotic membrane coverage Device: Ahmed Glaucoma Valve (AGV)
AGV implantation
Procedure: amniotic membrane coverage
single layer coverage of amniotic membrane


Ages Eligible for Study:   7 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with refractory glaucoma

Exclusion Criteria:

  • children under 7 years old
  • adults above 75 years old
  • uncooperative patients
  • patients underwent the operation for second time
  • patients with major operation with AGV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00893490

Contact: Shahin Yazdani, MD shahinyazdani@yahoo.com

Iran, Islamic Republic of
Ophthalmic Research Center Recruiting
Tehran, Iran, Islamic Republic of, 166666
Contact: Shahin yazdani, MD    98 21 22591616    labbafi@hotmail.com   
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
  More Information

Responsible Party: Ophthalmic Research Center
ClinicalTrials.gov Identifier: NCT00893490     History of Changes
Other Study ID Numbers: 8756 
Study First Received: May 4, 2009
Last Updated: May 4, 2009
Health Authority: Iran: Ethics Committee

Additional relevant MeSH terms:
Eye Diseases
Ocular Hypertension
Alkylating Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on May 05, 2016